logo

Merck & Co Inc. (MRK)



Trade MRK now with
  Date
  Headline
2/15/2019 7:01:28 AM Merck: FDA Grants Priority Review To Its Supplemental BLA For KEYTRUDA With Inlyta For Advanced RCC
2/14/2019 6:48:33 AM Merck To Present Data From Three Cohorts Of Phase 1b/2 KEYNOTE-365 Study
2/5/2019 6:47:14 AM Merck: FDA Accepts For NDA Review For Combination Of Imipenem/Cilastatin And Relebactam, And SNDA For ZERBAXA
2/4/2019 6:46:45 AM Merck Says CHMP Of EMA Adopted Positive Opinion Recommending KEYTRUDA In Combination With Chemotherapy
2/1/2019 6:45:42 AM Merck Q4 GAAP EPS $0.69; Non-GAAP EPS $1.04
1/30/2019 6:46:29 AM Merck Receives FDA Breakthrough Therapy Designation For V114
1/29/2019 4:31:12 PM Merck Elects Mary Ellen Coe To Board Of Directors
1/29/2019 3:11:48 PM Merck & Co Inc. (MRK) Declares Quarterly Dividend of $ 0.55, Record Date 3/15/2019
1/3/2019 6:48:10 AM Merck Says KEYTRUDA Receives Five New Approvals In Japan
1/3/2019 6:32:14 AM Merck Exercises Option For NGM Bio’ Investigational Insulin Sensitizer, NGM313, For Treatment Of NASH And Type2 Diabetes
1/2/2019 6:35:56 AM BriaCell Therapeutics Announces Imminent Clinical Use Of New Novel, Frozen Formulation For Bria-IMT